# US 2024/0197747 A1 · Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197747 A1
- Document ID: US20240197747A1
- Status: Published application
- Kind: A1
- Application number: 18/540,628
- Filed: 2023-12-14
- Published: 2024-06-20
- Earliest claimed: 2020-05-01
- Assignees: Acurastem Incorporated
- Applicants: AcuraStem, Inc.
- Inventors: Justin K. ICHIDA; Matthew STREMLAU; Hongyan ZHOU
- Web page: https://patentgrep.com/patent/US20240197747A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating viral infections including COVID-19 and compositions with a combination of (i) an inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) and (ii) an inhibitor of transmembrane serine proteinase 2 (TMPRSS-2).

## Claims

### Claim 1

A method for treating a subject having a viral infection comprising administering to the subject an effective amount of (i) a PIKfyve inhibitor and (ii) a TMPRSS-2 inhibitor, wherein the combination of the PIKfyve inhibitor and TMPRSS-2 inhibitor has a lower half-maximal inhibitory concentration for the viral infection than either the PIKfyve inhibitor or the TMPRSS-2 inhibitor alone.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 3 (depends on 1)

The method of claim 1, wherein the viral infection is a coronavirus infection.

### Claim 4 (depends on 3)

The method of claim 3, wherein the coronavirus is SARS-CoV-2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the viral infection is African swine flu infection, pox virus infection, Ebola virus infection, middle east respiratory syndrome virus (MERS) infection, JC polyomavirus (JC) infection, BK polyomavirus (BK) infection, Herpes Simplex Virus (HSV) infection, Marburg virus (MarV) infection, Venezuelan equine encephalitis virus (VEEV) infection, or Lymphocytic choriomeningitis virus (LCMV) infection.

### Claim 6 (depends on 1)

The method of claim 1, wherein the PIKfyve inhibitor comprises apilimod or a pharmaceutically acceptable salt thereof, APY0201, YM-201636, or any combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the TMPRSS-2 inhibitor comprises nafamostat or a pharmaceutically acceptable salt thereof, camostat or a pharmaceutically acceptable salt thereof, argatroban, otamixaban, letaxaban, darexaban, edoxaban, betrixaban, an anti-TMPRSS-2 antibody, an anti-TMPRSS-2 antigen binding fragment, or any combination thereof.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the PTKfyve inhibitor comprises (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol, Compounds 1-90, or any combination thereof.

### Claim 11

A method for treating a subject having a viral infection comprising administering to the subject an effective amount of (i) (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol, or a pharmaceutically acceptable salt thereof; and (ii) nafamostat, or a pharmaceutically acceptable salt thereof, wherein the combination of (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol and nafamostat has a lower half-maximal inhibitory concentration for the viral infection than either the (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol or nafamostat alone.

### Claim 12 (depends on 11)

The method of claim 11, wherein the viral infection is a coronavirus infection.

### Claim 13 (depends on 12)

The method of claim 12, wherein the coronavirus is SARS-CoV-2.

### Claim 14 (depends on 11)

The method of claim 11, wherein the viral infection is an African swine flu infection, pox virus infection, Ebola virus infection, middle east respiratory syndrome virus (MERS) infection, JC polyomavirus (JC) infection, BK polyomavirus (BK) infection, Herpes Simplex Virus (HSV) infection, Marburg virus (MarV) infection, Venezuelan equine encephalitis virus (VEEV) infection, or Lymphocytic choriomeningitis virus (LCMV) infection.

### Claim 15 (depends on 1)

The method of claim 1, wherein the PTKfyve inhibitor and/or the TMPRSS-2 inhibitor is formulated for administration through a route comprising oral, intravenous, or subcutaneous.

### Claim 16 (depends on 11)

The method of claim 11, wherein the PTKfyve inhibitor and/or the TMPRSS-2 inhibitor is formulated for administration through a route comprising oral, intravenous, or subcutaneous.

### Claim 17

A pharmaceutical composition comprising a PIKfyve inhibitor and TMPRSS-2 inhibitor.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the PIKfyve inhibitor comprises apilimod or a pharmaceutically acceptable salt thereof, APY0201, YM-201636, (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol, Compounds 1-90, or any combination thereof.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the TMPRSS-2 inhibitor comprises nafamostat or a pharmaceutically acceptable salt thereof, camostat or a pharmaceutically acceptable salt thereof, argatroban, otamixaban, letaxaban, darexaban, edoxaban, betrixaban, an anti-TMPRSS-2 antibody, an anti-TMPRSS-2 antigen binding fragment, or any combination thereof.

### Claim 20 (depends on 17)

A method of treating a subject having a viral infection comprising administering to the subject the pharmaceutical composition of claim 17.
